Assured Pharmacy sees spike in same-store sales
FRISCO, Texas — Same-store sales for specialty pharmacy group Assured Pharmacy rose 31.2% in November, compared with the year-ago period.
The company said the rise also represented a 6% increase over total sales in October.
"We are pleased with our November sales results and our continued patient growth with 3,182 patients serviced in the month of November," said Robert DelVecchio, Assured Pharmacy CEO. "As these sales figures reflect, we remain on track for increased sales and market share growth, improved earnings at the store level and stronger cash flow."
PhRMA expands board of directors
WASHINGTON — The Pharmaceutical Research and Manufacturers of America has added four new members to its board.
Joining PhRMA are Ian Read, Pfizer’s president and CEO; Jerzy Gruhn, Novo Nordisk president; Mark Iwicki, Sunovion Pharmaceuticals president and COO; and Staffan Schuberg, Lundbeck president.
"We are pleased to welcome four new biopharmaceutical heavyweights to join PhRMA’s board of directors," PhRMA president and CEO John Castellani said. "As leaders of one of the most research-intensive sectors in the United States, they bring to the table incredible insight and a keen understanding of the challenging economic, legislative and regulatory environments the industry faces on a daily basis."
Castellani added, "Despite these challenges, our board of directors has made it a top priority to build upon core patient-centered principles that guide our advocacy efforts as we work to advance public policies that foster medical innovation and help the United States maintain its global leadership in medical discovery. We look forward to working with all our board members to this aim in the months and years ahead."
Takeda settles patent suits relating to Actos
DEERFIELD, Ill., and OSAKA, Japan — Takeda and its subsidiary settled the patent suits it brought against generic drug makers that sought to develop their own versions of its diabetes treatment.
Takeda and Takeda Pharmaceuticals North America granted Mylan, Watson and Ranbaxy licenses to enter the U.S. market with generic Actos on Aug. 17, 2012, subject to regulatory approval, or earlier under certain circumstances. Mylan, Watson and Ranbaxy are first-filers of abbreviated new drug applications with paragraph IV certifications for Actos, and it is anticipated that the Food and Drug Administration will grant these companies 180-day marketing exclusivity, Takeda said.
Takeda also granted Alphapharm, Sandoz, Aurobindo, Dr. Reddy, Wockhardt, the Synthon defendants, Teva and Torrent licenses to enter the U.S. market with generic Actos beginning 180 days after the first-filers, subject to regulatory approval. Takeda has granted Teva a license to market an authorized generic version of Actos in the United States beginning on Aug. 17, 2012, or earlier under certain circumstances.
Takeda is the inventor and developer of Actos, which was commercially launched in the United States in 1999 for the treatment of Type 2 diabetes and has been prescribed for more than 10 million patients to date.